2 news items
Nurix Therapeutics Announces Board Chair Transition
NRIX
20 May 24
Committee. Ms. Gregory is currently Chair and Chief Executive Officer of Isometry Advisors, Inc., a biotechnology financial, strategy, and management
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
NRIX
9 Apr 24
therapeutic strategies to treat leukemias and lymphomas with CNS involvement," said Dr. Hansen. "The brain penetration of NX-5948 coupled with the clinical
- Prev
- 1
- Next